ADHD medications fall into two broad categories: stimulants (amphetamine class and methylphenidate class) and non-stimulants (atomoxetine, viloxazine, guanfacine, clonidine, and bupropion off-label). Stimulants are the most-prescribed and have the largest average effect sizes. Non-stimulants are less potent on average but fit better for many specific patients. Choosing between them is a clinical decision based on your individual situation.

Stimulants — the strengths

  • Larger average effect size than non-stimulants in randomized trials. About 70–80% of patients get a clinically meaningful response from a well-titrated stimulant.
  • Fast feedback loop. Effect is felt within 30–90 minutes; titration is faster (1–2 weeks per dose level).
  • Predictable curve. Onset, duration, and offset are well-characterized; you can match your formulation to your daily schedule.
  • Decades of safety and efficacy data. Methylphenidate has been used for ADHD since the 1960s; amphetamines since earlier.

Stimulants — the trade-offs

  • Schedule II controlled substances. Tighter prescribing rules, more pharmacy hassle, no easy refills.
  • Abuse and diversion potential. Most patients use stimulants safely, but the risk is real, especially in households with substance-use history.
  • Cardiovascular effects. Heart rate and blood pressure go up modestly. Significant cardiovascular history may contraindicate.
  • Sleep impact. Even well-timed stimulants can affect sleep onset.
  • Appetite suppression and weight loss. Common, sometimes problematic.
  • Can worsen anxiety in some patients with comorbid anxiety disorders.
  • Can unmask or worsen tics. Especially in patients with Tourette's or chronic tic disorders.
  • Don't last all day. Even longest-acting formulations cover ~12–14 hours, leaving an evening window unmedicated.

Non-stimulants — when each is a strong fit

Atomoxetine (Strattera) and viloxazine (Qelbree)

Norepinephrine-targeting non-stimulants. Steady all-day coverage, no controlled-substance regulation, no dopamine surge in striatum.

Strong fit when:

  • Stimulants caused intolerable anxiety, jitters, mood lability, or sleep disruption.
  • Substance-use history makes Schedule II problematic.
  • Comorbid anxiety — non-stimulants are typically anxiety-neutral or anxiety-improving.
  • Tic disorder — non-stimulants don't unmask tics.
  • You want consistent, all-day coverage rather than a 12-hour window.

Guanfacine ER (Intuniv) and clonidine ER (Kapvay)

Alpha-2 adrenergic agonists. Originally blood-pressure medications; the alpha-2A receptors in prefrontal cortex are involved in attention and impulse regulation.

Strong fit when:

  • Comorbid tics, oppositional behaviors, or significant emotional dysregulation.
  • Sleep onset issues — clonidine especially is often dosed at bedtime.
  • As an adjunct to stimulants when stimulants alone don't fully cover symptoms.
  • Pediatric use — both are FDA-approved for kids 6–17 specifically.

Caveats: significant sedation (especially clonidine), low blood pressure, must be tapered (not stopped abruptly), and generally less effective than stimulants for core attention symptoms.

Bupropion (Wellbutrin)

Off-label for ADHD; on-label for depression and smoking cessation. A norepinephrine-dopamine reuptake inhibitor.

Strong fit when:

  • Comorbid depression — treats both at once.
  • Stimulants and other non-stimulants haven't worked.
  • Smoking cessation is also a goal.

Caveats: not FDA-approved for ADHD specifically (off-label), seizure risk in patients with eating disorders or seizure history, can cause insomnia.

Standard clinical sequence in adults

This is the typical pattern, though every clinician individualizes:

  1. Try a stimulant first — usually the methylphenidate or amphetamine class your clinician prefers based on your profile.
  2. If first stimulant doesn't work or has intolerable side effects, try the other stimulant class.
  3. If both stimulant classes fail, move to a non-stimulant — usually atomoxetine or viloxazine.
  4. If single-medication therapy isn't sufficient, consider combinations (stimulant + alpha-2 agonist, stimulant + atomoxetine, etc.) — these are common and well-supported.

For pediatric patients, especially with comorbid tics, anxiety, or behavioral issues, non-stimulants are sometimes used as first-line. For patients with substance-use history, non-stimulants are often preferred from the start.

Compare them directly

The medication comparison tool shows all FDA-approved options side-by-side: mechanism, duration, onset, side effects, dose ranges, schedule. The right answer for you is whatever balances the clinical factors your prescriber identifies — and matches the constraints of your life.